Abliva
Abliva AB Interim Report January – March 2023
MARKN.
Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354
First Quarter Summary
Important events January — March 2023
- Abliva appointed Dag Nesse as Vice President of Clinical Operations. Mr. Nesse has joined the company’s management team.
- The U.S. Patent and Trademark Office granted a composition of matter patent for the NV354 compound.
- An Extraordinary General Meeting was held on March 8.
Important events after the reporting period
- Abliva’s drug candidate NV354 was granted Orphan Drug Designation (ODD) in the U.S. for the treatment of mitochondrial disease.
- Abliva’s Annual General Meeting was held on May 5. All proposals were passed by the general meeting. For more information, see https://abliva.com/news/resolutions-from-annual-general-meeting-in-abliva-ab-publ-on-may-5-2023/.
Financial information
January-March 2023*
- Net revenues: SEK 0 (0)
- Other operating income: SEK 1,055,000 (0)
- Loss before tax: SEK 16,092,000 (22,028,000)
- Loss per share before dilution: SEK 0.02 (0.05)
- Diluted loss per share: SEK 0.02 (0.05)
* APM Alternative performance measures, see definition on page 20.
The complete Interim report is available for download below and through Abliva's website www.abliva.com.
Datum | 2023-05-23, kl 08:30 |
Källa | MFN |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!